News News

CONTACT:

Sirnaomics, Inc.
Michael Molyneaux MD MBA
Chief Medical Officer
michaelmolyneaux@sirnaomics.com

ICR Healthcare

Investors:
Stephanie Carrington
Tel: +1 646 277 1282
Stephanie.Carrington@icrinc.com

Media: James Heins
Tel: +1 203 682 8251
James.Heins@icrinc.com

Sirnaomics Dmitry S News
September 25, 2018 Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer

Dr. Samarsky is one of the pioneers and an internationally recognized expert in the field of RNAi therapeutics. Dr. Samarsky will have two roles: (1) to lead Sirnaomics’ RNAi technology development and secure its leadership position; and (2) to facilitate technology collaborations and therapeutic partnerships.

Sirnaomics News Placeholder 01
August 16, 2018 Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of CCA

Sirnaomics announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first oncology IND application. The IND approval will allow for the study of the Company’s lead product candidate, STP705, in patients with advanced cholangiocarcinoma (CCA).

Sirnaomics News Placeholder 05
July 27, 2018 Sirnaomics Appoints Dr. Evans as CSO to Lead Preclinical Antifibrosis & Anticancer RNAi Programs

Sirnaomics announced today that David Evans, Ph.D., a co-founder of the company, has been appointed as Chief Scientific Officer.

Sirnaomics News Placeholder 04
June 6, 2018 Sirnaomics Closed Series C1 Financing of US$25 Million and Expands Clinical Programs

This round of financing was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.

Sirnaomics China
May 3, 2018 Dr. Steven Long Joins Sirnaomics Senior Management Team as Head of China Clinical Studies

Dr. Long will be responsible for clinical studies performed in China. His extensive experience and knowledge in preclinical and clinical regulations will strengthen Sirnaomics clinical programs for novel siRNA therapeutic development in China.

1 2 3 4 5 7